Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027651 (tumor)
 685,946 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Chemiluminescence (CL) is an index of both the generation of and reactions mediated by O2-. and 1O2. The tumor promoter, 12-O-tetradecanoylphorbol-13-acetate (TPA), is a potent stimulator of CL by human polymorphonuclear leukocytes; treatment with TPA (100 ng/ml) provokes a CL response that peaks within five min and persists for over 30 min. The response is proportional to concentration over the range of one to 100 ng/ml. The ability of different phorbol diesters to stimulate both CL and O2-. production correlates with their relative activities as tumor promoters in vivo. Non-phorbol diester tumor promoters such as iodoacetic acid, anthralin, and tween 60 are inactive in this system. The TPA-mediated stimulation of CL can be inhibited by retinoids; cells preincubated for 15 min with 100 microM retinoic acid show only a marginal CL response to TPA. Addition of retinoic acid to resting polymorphonuclear leukocytes results in a transient burst of CL without concomitant O2-. release, observations indicative of an excitable substrate. A similar CL response is seen when retinoic acid is incubated with potassium superoxide in a cell-free system. 5,6-Epoxyretinoic acid, and even more effective inhibitor of TPA-stimulated CL than retinoic acid when added simultaneously with TPA, does not undergo these two CL reactions. Thus, it appears that retinoic acid may undergo oxidative activation to a species that exert enhanced antipromoter activities. Polymorphonuclear leukocytes provide a useful system for exploring the roles of reactive oxygen species in the mechanism of action of both TPA and retinoic acid.
 ...
PMID:Inhibiton of phorbol ester-stimulated chemiluminescence in human polymorphonuclear leukocytes by retinoic acid and 5,6-epoxyretinoic acid. 625 61

Fifteen established tumor promoters belonging to different chemical groups were tested for their ability to induce Epstein-Barr virus (EBV)-specific early antigens (EA) in EBV-genome-positive nonproducer Raji cells. Saccharin (a promoter in urinary bladder carcinogenesis), DDT (a promoter in liver carcinogenesis), anthralin and iodoacetic acid (promoters in skin carcinogenesis) gave a significant induction with a maximum of induced cells of 20% (8 mg/ml), 0.8% (20 micrograms/ml), 0.8% (100 ng/ml) and 0.7% (0.4 micrograms/ml), respectively. In addition, after combined application with a noninducing dose (0.2 ng/ml) of 12-O-tetradecanoyl-phorbol-13-acetate (TPA), seven additional tumor promoters induced 0.3-2.1% EA-positive cells two days after treatment. The results indicate that in addition to mouse skin tumor promoters such as diterpene esters, several compounds reported to possess tumor-promoting activity in other types of tissue induce EBV. The data suggest that EBV induction is an effect commonly exerted by this group of compounds which should be very useful in screening for environmental tumor promoters.
 ...
PMID:Induction of Epstein-Barr virus antigens by tumor promoters for epidermal and nonepidermal tissues. 632 26

Nude mice injected subcutaneously with CSF-producing human pancreatic carcinoma (MIA PaCa-2) cells developed tumors accompanied by a rise in serum CSF activity, granulocytosis, and expanded marrow granulocyte pools, the extent of all of which correlated with tumor size. The tumor origin of the CSF was demonstrated by neutralization with the specific antibody. Resection of the tumor resulted in restoration of normal granulocyte levels. These observations lend further support to an in vivo role for CSF in the regulation of granulopoiesis.
 ...
PMID:Further evidence supporting an in vivo role for colony-stimulating factor. 633 13

Potent tumor promoters such as 12-O-tetradecanoylphorbol 13-acetate (TPA) and teleocidin, rapidly evoked a dose-dependent stimulation of concanavalin A (Con A)-induced cap formation in mouse T lymphocytes. The effect was reversible upon removal of the drugs. Weaker tumor promoters, phorbol didecanoate, phorbol dibenzoate and iodoacetic acid stimulated capping to a lower extent. Mezerein, a phorbol-related macrocyclic diterpene derivative, which acts as a second-stage promoter was also active in increasing the number of caps. In contrast, 4 alpha-phorbol didecanoate and phorbol which are devoid of tumor promoting activity, did not affect capping. Anti-promoting glucocorticoids inhibited capping stimulation. Flow cytofluorometric analysis of Con A binding has shown that TPA did not modify the lectin binding to surface receptors. TPA-facilitated capping was energy-dependent. Cytochalasin B prevented the TPA-induced response whereas colchicine was ineffective. Phenothiazines fully inhibited the TPA effect, thus suggesting that tumor-promoter-mediated lectin receptor redistribution may be ascribed to the facilitation of a Ca2+-dependent process involving the submembrane actin filaments.
 ...
PMID:Tumor promoters enhance cap formation in mouse thymocytes. 660 Apr 16

Peritoneal exudate macrophage monolayers (PEMM) from C57BL/6 and DBA/2 mice inoculated ip with tumor allografts were induced to release in vitro labile cell toxin(s), herein called "macrophage cytotoxin(s)" (MCT). Macrophages released MCT spontaneously for a short interval when initially established as monolayers, and they were reinduced to secrete MCT by exposure to allogeneic and syngeneic tumor cells (but not to normal cells) and by exposure to polyinosinic-polycytidylic acid (poly I . poly C) and lipopolysaccharide (LPS). PEMM from normal mice treated ip 3 days previously with thioglycollate were also induced to release toxins in vitro. These cells did not release MCT spontaneously before or after treatment with neoplastic cells but were induced to release MCT by exposure to poly I . poly C or LPS. Resident peritoneal macrophages did not release MCT either spontaneously or after treatment with tumor cells, poly I . poly C, or LPS. MCT released from alloimmune mice stimulated with syngeneic or allogeneic tumor cells were resolved by molecular sieving into a major peak at 140,000--160,000 daltons, called "alpha-MCT," and into a minor peak at 60,000 daltons, called "beta-MCT." However, supernatants from thioglycollate-induced PEMM, stimulated with poly I . poly C or LPS, appeared to be composed entirely of the alpha-class. alpha-MCT from poly I . poly C-stimulated PEMM caused 31--56% lysis of syngeneic EL-4 and allogeneic L-929, NS-1, and YAC-1 tumor cells in vitro but was not cytotoxic for normal cells. Secretion of the MCT by PEMM derived from thioglycollate-treated animals stimulated with poly I . poly C was inhibited by colchicine, emetine, iodoacetic acid, trypan blue, and cytochalasin B.
 ...
PMID:Inducible macrophage cytotoxins. I. Biokinetics of activation and release in vitro. 695 64

[20-(3)H]Phorbol 12,13-dibutyrate bound to particulate preparations from chicken embryo fibroblasts in a specific, saturable, reversible fashion. Equilibrium binding occurred with a K(d) of 25 nM; this value is very close to the 50% effective dose (ED(50)), 50 nM, previously determined for the biological response (induction of fibronectin loss) in growing chicken embryo fibroblasts. At saturation, 1.4 pmol of [20-(3)H]phorbol 12,13-dibutyrate was bound per mg of protein (approximately 7 x 10(4) molecules per cell). Binding was inhibited by phorbol 12-myristate 13-acetate (K(i) = 2 nM), mezerein (K(i) = 180 nM), phorbol 12,13-dibenzoate (K(i) = 180 nM), phorbol 12,13-diacetate (K(i) = 1.7 muM), phorbol 12,13,20-triacetate (K(i) = 39 muM), and phorbol 13-acetate (K(i) = 120 muM). The measured K(i) values are all within a factor of 3.5 of the ED(50) values of these derivatives for inducing loss of fibronectin in intact cells. Binding was not inhibited by the inactive compounds phorbol (10 mug/ml) and 4alpha-phorbol 12,13-didecanoate (10 mug/ml) or by the inflammatory but nonpromoting phorbol-related diterpene esters resiniferatoxin (100 ng/ml) and 12-deoxyphorbol 13-isobutyrate 20-acetate (100 ng/ml). These data suggest that biological responses to the phorbol esters in chicken embryo fibroblasts are mediated by this binding activity and that the binding activity corresponds to the phorbol ester target in mouse skin involved in tumor promotion. Binding was not inhibited by the nonphorbol promoters anthralin (1 muM), phenol (1 mM), iodoacetic acid (1.7 muM), and cantharidin (75 muM), or by epidermal growth factor (100 ng/ml), dexamethasone acetate (2 muM), retinoic acid (10 muM), or prostaglandin E(2) (1 muM). These agents thus appear to act at a target distinct from that of the phorbol esters.
 ...
PMID:Specific binding of phorbol ester tumor promoters. 696 93

L-Canavanine (CAV) is a potent L-arginine antagonist, produced by legumes such as the jack bean, Canavalia ensiformis. CAV is cytotoxic to MIA PaCa-2 human pancreatic cancer cells. We sought to determine whether CAV's efficacy as an anticancer agent might be increased in combination with 5-fluorouracil (5-FU), a pyrimidine antimetabolite with activity against solid tumors. Using optimal conditions for the expression of CAV's cytotoxicity against MIA PaCa-2 cells, CAV was more cytotoxic to the cells than 5-FU. The combination of both drugs at a fixed molar ratio of 1:1 exhibited synergistic effects in the cells as determined by combination index analysis. The combination of 5-FU:CAV was tested at a ratio of 5:1 and exhibited antagonism at lower effect levels, additivity at 50% effect levels and slight synergism at higher effect levels. A 10:1 combination of both drugs (5-FU:CAV) exhibited antagonistic effects at all levels. When the drugs were combined at a molar ratio of 20:1, increased antagonism was observed. When CAV (1.0 or 2.0 g/kg daily) and/or 5-FU (35 mg/kg daily) was administered to colonic tumor-bearing rats for five consecutive days, the antitumor activity of the drug combination was significantly greater than the combined effects of either drug alone. However, the body weight loss experienced by CAV-treated rats was increased in those rats exposed to a combination of both drugs. These studies using different tumors provide in vitro and in vivo evidence that combination therapy offers a viable means of improving CAV's intrinsic efficacy while decreasing the concentration of 5-FU required to produce the same cytotoxic effect.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Combination therapy with 5-fluorouracil and L-canavanine: in vitro and in vivo studies. 757 63

Cocultivation of cells from the gamma-irradiated D2XRII murine bone marrow stromal cell line with an interleukin-3/granulocyte-macrophage colony-stimulating factor (GM-CSF)-dependent hematopoietic progenitor cell line FDC-P1JL26 stimulates the emergence of factor-independent hematopoietic cell sublines. Several lines of evidence suggested that M-CSF or a protein antigenically related to M-CSF, termed leukemogenic stromal factor (LSF), that was expressed by D2XRII cells may have played a role in the emergence of the factor-independent sublines. In an effort to isolate a factor antigenically related to M-CSF, molecular clones were isolated from a D2XRII cDNA library that hybridized to a mouse M-CSF genetic probe. Two of these molecular clones, designated 60.8.2 and 6452, contained an 885-bp deletion in the M-CSF coding region. Such a cDNA clone has not been previously described in the mouse, but a cDNA clone homologous to it has been isolated from a human pancreatic tumor cell line, MIA-PaCa-2. Three transcripts (4.8, 3.4, and 1.8 kb) were detected that hybridized to an oligonucleotide probe that was specific to RNA transcripts containing the 60.8.2 deletion. The level of the 1.8-kb transcript was not detectably induced by ionizing irradiation; however, the levels of the 4.8-kb and 3.4-kb transcripts and two other M-CSF transcripts of sizes to 4.4 kb and 2.3 kb showed a 1.4- to 2.2-fold increase after gamma irradiation. Reverse transcription-polymerase chain reaction showed that the deletion-specific transcript(s) was detected in multiple mouse bone marrow stromal cell lines and in normal mouse tissues. The present studies establish the existence of an increased spectrum of murine M-CSF transcripts in bone marrow stromal cells and other tissues. This complexity of transcripts along with their increased accumulation after irradiation provides additional evidence for a role of proteins encoded by M-CSF transcripts in the response of bone marrow stromal cells to ionizing irradiation.
 ...
PMID:Cloning and expression of unique murine macrophage colony-stimulating factor transcripts. 778 Jan 34

We have previously reported that the cholecystokinin antagonist MK-329 (also known as L-364,718 or devazepide) synergistically enhances sensitivity to cisplatin (DDP) in MIA-PaCa2 human pancreatic cancer cells in tissue culture. In this study, we examined the ability of MK-329 to modulate DDP sensitivity in vivo using MIA-PaCa2 pancreatic cancer xenografts growing subcutaneously in athymic nude mice. Twenty-four hours after tumor inoculation, mice received either DDP intraperitoneally, MK-329 subcutaneously, both DDP and MK-329 or drug vehicles alone. Both DDP and MK-329 alone caused a reduction in the rate of tumor growth. The combination of DDP and MK-329 resulted in enhanced tumor growth delay compared to DDP or MK-329 treated mice. Although MK-329 alone was not nephrotoxic, the addition of MK-329 to DDP treatment resulted in a significant increase in weight loss and nephrotoxicity compared to mice treated with DDP alone; this was reflected by an increase in the plasma BUN levels. Although we believe that the enhanced anti-tumor effect of DDP/MK-329 combination therapy may be independent MK-329's capability to block CCK receptors, the role of CCK receptor blockade in potentiating DDP-induced nephrotoxicity less clear.
 ...
PMID:In vivo modulation of cisplatin cytotoxicity by the cholecystokinin antagonist MK-329 in human pancreatic cancer xenografts. 787 89

Sarcophytol A (SaA), a cembrane-type diterpene isolated from the marine soft coral Sarcophyton glaucum showed anticancer and cancer preventive effects in two different experiments. Growth of transplanted human pancreatic cancer cells (MIA paca-2, 1 x 10(7)) in nude mice (BALB/C 4W female) (Experiment 1) and pancreatic carcinogenesis induced by N-nitrobis-(2-hydroxypropyl) amine (BHP, 500 mg/kg) in Syrian golden hamsters (7W female) (Experiment 2) were inhibited by feeding the animals a diet containing 0.01% SaA. In Experiment 1, on day 29 after transplantation, tumor volume was significantly less in the SaA group than in the control group (1,759 + 310 mm3 vs. 2,364 + 467 mm3) (p < 0.05). In Experiment 2, the incidence of pancreatic tumors in the SaA group was 42.8% and that in the control group was 90.0% at 25-27 weeks. Thus, pancreatic carcinoma developed more slowly in the SaA group than in the control group. In addition, the incidence of atypical ductal hyperplasia and carcinoma in situ was lower in the SaA group. These results indicate that oral SaA administration is an effective vehicle for inhibition of certain types of cancer in hamsters.
 ...
PMID:Sarcophytol A: a new chemotherapeutic and chemopreventive agent for pancreatic cancer. 793


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>